M31 Sells Adaptica to Chinese Eye Care Group

Padova, Italy – May 14, 2018 – Alira Health is pleased to announce its role as exclusive financial advisor to M31 Italia and Adaptica with the sale of Adaptica to an unnamed Chinese eye care group in China.

M31 Italia has sold 100% of Adaptica, an Italian manufacturer of portable devices for the detection and correction of refractive errors and visual defects, to the unnamed eye care group in China. The amount of the deal was not disclosed.

Founded in 2009 as a spin-off of the Padua University’s Adaptive Optics Lab by Tommaso Occhipinti, Sales and Marketing Director, and led by Gianluigi Meneghini, CEO, Adaptica applied space and astronomy technologies to the field of ophthalmology, bringing innovations for both the measurement of refractive defects and the prescription of custom lenses.

Adaptica will be empowered by the international scientific and business network of the new owner, which plans to develop new vision solutions.

The transaction was managed by Orrick Italia for Adaptica’s transferring shareholders and by Clifford Chance for the Chinese buyer group.

Adaptica’s products include 2WIN, a portable refractometer, and VisionFit, a portable phoropter that allows rapid, automatic eye exams in many situations, including with non-cooperative patients. Kaleidos, Adaptica’s latest development, is an instrument that simplifies examinations by ophthalmologists and optometrists.

ABOUT ADAPTICA 

Adaptica was founded in 2009 as a spin-off of the University of Padova, Italy specializing in adaptive optics and optoelectronics applied to Industry and astronomical research. Adaptica leverages on its technological know-how and competences in astronomy to move from a better vision of the universe and its galaxies towards exploring vision and the human eye. Adaptica expanded into health-care, with a particular focus on vision and eye-care. It develops and manufactures smart, mobile, easy to use diagnostic pieces of equipment that are currently distributed in over 40 countries worldwide.